Akeso Biomedical
Akeso Biomedical is a food safety company dedicated to developing innovative, antibiotic-free solutions to reduce bacterial infections in farm animals and improve food safety. Their proprietary Fe3C technology targets pathogens like Campylobacter, Salmonella, and E. coli, aiming to prevent foodborne illnesses and enhance animal health.
Industries
Nr. of Employees
small (1-50)
Akeso Biomedical
2400 District Ave., Burlington, MA 01803
Patents
Products
Fe3C-derived feed additive for poultry (iron chelate)
A feed-additive candidate based on iron-complex chemistry intended to prevent gastrointestinal colonization by Campylobacter and other enteropathogens in poultry, with observed improvements in weight gain and feed conversion in trials.
Fe3C antimicrobial platform (research pipeline)
A research platform based on iron-complex chemistry being evaluated for broader applications including reduction of enteropathogens in multiple food-producing species and potential anti-biofilm applications outside of feed.
Fe3C-derived feed additive for poultry (iron chelate)
A feed-additive candidate based on iron-complex chemistry intended to prevent gastrointestinal colonization by Campylobacter and other enteropathogens in poultry, with observed improvements in weight gain and feed conversion in trials.
Fe3C antimicrobial platform (research pipeline)
A research platform based on iron-complex chemistry being evaluated for broader applications including reduction of enteropathogens in multiple food-producing species and potential anti-biofilm applications outside of feed.
Services
Design and execution of in vitro studies, pen-based trials and farm studies to evaluate feed-additive candidates for pathogen suppression and zootechnical performance.
Preparation and filing of regulatory submissions for zootechnical feed-additive approval with regional authorities.
Licensing of platform technology originating from academic research and negotiation of distribution or partnership agreements for product launch.
Design and execution of in vitro studies, pen-based trials and farm studies to evaluate feed-additive candidates for pathogen suppression and zootechnical performance.
Preparation and filing of regulatory submissions for zootechnical feed-additive approval with regional authorities.
Licensing of platform technology originating from academic research and negotiation of distribution or partnership agreements for product launch.
Expertise Areas
- Feed additive development for poultry and livestock
- Antimicrobial and anti-biofilm research
- In vivo animal trial design and execution
- Regulatory submissions for zootechnical feed additives (EU)
Key Technologies
- Iron-complex antimicrobial chemistry (Fe3C/iron chelates)
- Anti-adhesion / anti-biofilm mechanism targeting bacterial surface adhesion proteins
- Zootechnical feed additive formulation
- In vitro microbiology and biofilm assays
News & Updates
Akeso Biomedical has licensed a new class of compounds, Fe3C, with broad-spectrum activity against bacteria like Campylobacter, to treat bacterial infections and microbial biofilms, especially in poultry.
Akeso Biomedical has applied for approval of its feed additive TYPLEX Chelate in Europe, designed to prevent pathogenic bacteria from adhering to the intestinal lining of birds, thereby reducing foodborne illnesses.
Greg W. Lee, former president of Tyson Foods International, joined Akeso's board to help commercialize food safety technology targeting bacteria like Salmonella, Campylobacter, and E. coli in chicken.
Scott Roth, hedge fund manager, joined the board to support Akeso's growth and development of its feed additive technologies for animal health.
The company's proprietary technology is being used to develop feed additives that prevent food poisoning by bacteria such as Campylobacter, which causes more foodborne illness cases in the EU than Salmonella, E. coli, and Listeria combined.
A publication highlighting the effectiveness of TYPLEX® Chelate in inhibiting bacterial biofilm formation in poultry.
Akeso Biomedical has licensed a new class of compounds, Fe3C, with broad-spectrum activity against bacteria like Campylobacter, to treat bacterial infections and microbial biofilms, especially in poultry.
Akeso Biomedical has applied for approval of its feed additive TYPLEX Chelate in Europe, designed to prevent pathogenic bacteria from adhering to the intestinal lining of birds, thereby reducing foodborne illnesses.
Greg W. Lee, former president of Tyson Foods International, joined Akeso's board to help commercialize food safety technology targeting bacteria like Salmonella, Campylobacter, and E. coli in chicken.
Scott Roth, hedge fund manager, joined the board to support Akeso's growth and development of its feed additive technologies for animal health.
The company's proprietary technology is being used to develop feed additives that prevent food poisoning by bacteria such as Campylobacter, which causes more foodborne illness cases in the EU than Salmonella, E. coli, and Listeria combined.
A publication highlighting the effectiveness of TYPLEX® Chelate in inhibiting bacterial biofilm formation in poultry.